Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529138 · ClinicalTrials.gov registry record · Phase 1
Study of Axitinib and Temsirolimus in Solid Tumors
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01529138 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 13 participants.
The verdict
NCT01529138, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial.
Interventions
- DRUG Axitinib
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529138
The ClinicalTrials.gov registry entry for NCT01529138 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Axitinib is the first listed.
NCT01529138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01529138 about?
NCT01529138 is a clinical study titled "Study of Axitinib and Temsirolimus in Solid Tumors". This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has no...
What is the current status of trial NCT01529138?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-10. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01529138?
The interventions under investigation include: Axitinib (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01529138?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.